Cargando…

PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer

Overcoming cellular growth restriction, including the evasion of cellular senescence, is a hallmark of cancer. We report that PAK4 is overexpressed in all human breast cancer subtypes and associated with poor patient outcome. In mice, MMTV-PAK4 overexpression promotes spontaneous mammary cancer, whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Tânia D. F., Zhuang, Ting, Lorent, Julie, Turco, Emilia, Olofsson, Helene, Masia-Balague, Miriam, Zhao, Miao, Rabieifar, Parisa, Robertson, Neil, Kuiper, Raoul, Sjölund, Jonas, Spiess, Matthias, Hernández-Varas, Pablo, Rabenhorst, Uta, Roswall, Pernilla, Ma, Ran, Gong, Xiaowei, Hartman, Johan, Pietras, Kristian, Adams, Peter D., Defilippi, Paola, Strömblad, Staffan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689091/
https://www.ncbi.nlm.nih.gov/pubmed/31399573
http://dx.doi.org/10.1038/s41467-019-11510-4
Descripción
Sumario:Overcoming cellular growth restriction, including the evasion of cellular senescence, is a hallmark of cancer. We report that PAK4 is overexpressed in all human breast cancer subtypes and associated with poor patient outcome. In mice, MMTV-PAK4 overexpression promotes spontaneous mammary cancer, while PAK4 gene depletion delays MMTV-PyMT driven tumors. Importantly, PAK4 prevents senescence-like growth arrest in breast cancer cells in vitro, in vivo and ex vivo, but is not needed in non-immortalized cells, while PAK4 overexpression in untransformed human mammary epithelial cells abrogates H-RAS-V12-induced senescence. Mechanistically, a PAK4 – RELB - C/EBPβ axis controls the senescence-like growth arrest and a PAK4 phosphorylation residue (RELB-Ser151) is critical for RELB-DNA interaction, transcriptional activity and expression of the senescence regulator C/EBPβ. These findings establish PAK4 as a promoter of breast cancer that can overcome oncogene-induced senescence and reveal a selective vulnerability of cancer to PAK4 inhibition.